Vascular endothelial growth factor receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 13, 2012, Pages 8458-8471

  Cho, Yang Kyung ^a,b   Zhang, Xiaohui ^a   Uehara, Hironori ^a   Young, Jason R ^a   Archer, Bonnie ^a   Ambati, Balamurali ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHOLINO OLIGONUCLEOTIDE; TRIAMCINOLONE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; GLUCOCORTICOIDS; GRAFT SURVIVAL; KERATOPLASTY, PENETRATING; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MORPHOLINOS; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84873357686     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10408     Document Type: Article

References (44)

1. Niederkorn JY, Larkin DFP. Immune privilege of corneal allografts. Ocul Immunol Inflamm. 2010;18:162-171.
2. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
3. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
4. Santos LN, de Moura LR, Fernandes BF, Cheema DP, Burnier MNJ. Histopathological study of delayed regraft after corneal graft failure. Cornea. 2011;30:167-170.
5. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of Topical and subconjunctival Bevacizumab in High-Risk Corneal Transplant survival. Invest Ophthalmol Vis Sci. 2010;51: 2411-2417.
6. Niederkorn JY. High risk corneal allografts and why they lose their immune privilege. Curr Opin Allergy Clin Immunol. 2010;10:493-497.
7. Weisbrod DJ, Sit M, Naor J, Slomovic AR. Outcomes of repeat penetrating keratoplasty and risk factors for graft failure. Cornea. 2003;22(5);429-434.
8. Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. Vol 2, Chapter 121. 3rd ed: Mosby Elsevier. 2011;1409-1416.
9. Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. Vol 2, Chapter 128. 3rd ed: Mosby Elsevier. 2011;1495-1509.
10. Cursiefen C, Lu, Chen, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
11. Rocher N, Behar-Cohen F, Pournaras JA, et al. Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. Mol Vis. 2011;17:104-112.
12. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
13. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
14. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14:528-552.
15. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol. 2001; 33:409-420.
16. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39:469-478.
17. Kerber M, Reiss Y, Wickersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008;68:7342-7351.
18. Huckle WR, Roche RI. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem. 2004;93:120-132.
19. Rahimi N, Golde TE, Meyer RD. Identification of ligandinduced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res. 2009;69: 2607-2614.
20. Heasman J. Morpholino oligos: making sense of antisense? Dev Biol. 2002;243:209-214.
21. Ekker SC, Larson JD. Morphant technology in model developmental systems. Genesis. 2001;30:89-93.
22. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta. 1999;1489:141-158.
23. Summerton J. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem. 2007;7: 651-660.
24. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187-195.
25. Cho YK, Uehara H, Young JR, Archer B, Zhang X, Ambati BK. Vascular endothelial growth factor receptor 1 morpholino decreases angiogenesis in a murine corneal suture model. Invest Ophthalmol Vis Sci. 2012;53:685-692.
26. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-704.
27. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997.
28. Owen LA, Uehara H, Cahoon J, Huang W, Simonis J, Ambati BK. Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS ONE. 2012;7:e33576.
29. Uehara H, Cho YK, Simonis J, et al. Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR) [published online ahead of print September 20, 2012]. FASEB J. 2012;fj.12-213835.
30. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000; 41:2514-2522.
31. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamberassociated immune deviation induction. Invest Ophthalmol Vis Sci. 1995;36:2176-2185.
32. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of Graft survival by vascular endothelial growth factor A neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126:71-77.
33. Yamagami S, Hamrah P, Zhang Q, Liu Y, Huq S, Dana MR. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Molecular Vision. 2005;11:632-640.
34. Wu BLY, Morcos PA, Doran TJ, Lu P, Lu QL. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Molecular Therapy. 2009;17:864-871.
35. McCulley JP. The Circulation of fluid at the limbus (flow and diffusion at the limbus). Eye. 1989;3:114-120.
36. Zhang H, Grimaldo S, Yuen D, Chen L. Combined blockade of VEGFR-3 and VLA-1 markedly promotes high risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2011;52:6529-6535.
37. Amescua G, Collings F, Sidani A, et al. Effect of CXCL-1/KC production in high risk vascularized corneal allografts on T cell recruitment and graft rejection. Transplantation. 2008; 85:615-625.
38. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
39. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nature Medicine. 2009;15:1023-1030.
40. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184:535-539.
41. Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA. Corneal graft survival and visual outcome. A multicenter study. Corneal Transplant Follow-up Study Collaborators. Ophthalmology. 1994;101:120-127.
42. Gore SM, Vail A, Bradley BA, Rogers CA, Easty DL, Armitage WJ. HLA-DR matching in corneal transplantation. Systemic review of published evidence. Corneal transplantation followup study collaborators. Transplantation. 1995;15:1033-1039.
43. Unal M, Yucel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 2008;92:1411-1414.
44. Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011;129:445-452.